Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A bitter lesson, but tissue engineering learns to refocus on commercial realities

This article was originally published in Clinica

Executive Summary

During the last 18 months there has been a dramatic turn around in the commercial world of tissue engineering. The lessons being learnt are providing a new generation of tissue engineers with a solid foundation upon which to build a successful industry, says Chris Mason FRCS, of the Advanced Centre for Biochemical Engineering, UCL, London. The following is an excerpt of a paper prepared by Dr Mason for the MDT 2004 meeting in Birmingham, UK.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT057223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel